On April 19, 2018, Lifetech (1302.HK) was awarded as "listed company with the Best Medical Devies and Diagnosis " at the 2018 CHC ·7th China Healthcare Investment CEO Conference.
This year's conference released the Healthcare Industry Investment Merit List for the first time, which was the results of the vote by more than 6,000 professionals who had previously attended the conference.
(Fig.: Mr. Zhu Shengli, Director of Investor Relations of Lifetech (second from right) accepted the award on behalf of the company)
The steady development of the structural heart disease products and peripheral vascular products of Lifetech, the steady promotion of the only Chinese left atrial appendage (LAA) closure systems currently available globally, the launch of the implantable cardiac pacemakers that have reached the current international technological and quality levels onto the Chinese market, and a series of innovative products such as the revolutionary sirolimus-eluting iron absorbable coronary stent system the clinical trial of which has been launched will gradually lead the company to a higher level.